Global CAR T Cell Therapy Market Size by Target Antigen (CD19, CD22), by Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma), & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1261434
  • |
  • Publishe Date : September 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

Chimeric Antigen Receptor (CAR) T cell therapy is an immunotherapy used for cancer treatment. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells.

The global CAR T cell therapy market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. The growing prevalence of cancer across the world, technological advancement & reliable treatment for cancer, growing pharmaceutical industry, and rise in the number of cell therapy clinical studies are driving the growth of the market globally. However, side-effects of CAR T-cell therapy and high cost of treatment are the major factors expected to hamper the growth of the global market.

The global CAR T cell therapy market is primarily segmented based on different target antigen, application, and regions. On the basis of target antigen, the market is divided into CD19, CD22, and others. The applications covered in the study include acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, South America, and MEA.

On the basis of target antigen, the market is split into:
* CD19
* CD22
* Others

On the basis of application, the market is split into:
* Acute Lymphoblastic Leukemia
* Diffuse Large B-Cell Lymphoma
* Other Applications

Moreover, the market is classified based on regions and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Novartis AG
* Kite Pharma
* Pfizer, Inc.
* Cellectis
* Autolus Therapeutics PLC
* CARsgen Therapeutics
* Juno Therapeutics
* Sorrento Therapeutics
* Legend Biotech
* Mustang Bio

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, target antigen, and application market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions, target antigen, and application with qualitative and quantitative information and facts

Target Audience:
* CAR T Cell Therapy Providers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global CAR T Cell Therapy Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global CAR T Cell Therapy Market - Porter\'s Five Forces Analysis
4.4. Global CAR T Cell Therapy Market - PESTEL Analysis

5. Global CAR T Cell Therapy Market, by Target Antigen
5.1. Global CAR T Cell Therapy Market, Size and Forecast, 2015-2026
5.2. Global CAR T Cell Therapy Market, by CD19, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global CAR T Cell Therapy Market, by CD22, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.4. Global CAR T Cell Therapy Market, by Others, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026

6. Global CAR T Cell Therapy Market, by Application
6.1. Global CAR T Cell Therapy Market, Size and Forecast, 2015-2026
6.2. Global CAR T Cell Therapy Market, for Acute Lymphoblastic Leukemia, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global CAR T Cell Therapy Market, for Diffuse Large B-Cell Lymphoma, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global CAR T Cell Therapy Market, for Other Applications, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026

7. Global CAR T Cell Therapy Market, by Region
7.1. CAR T Cell Therapy Market Regional Analysis, 2015-2026
7.2. Global CAR T Cell Therapy Market Revenue (USD Million) by Region, 2015-2026
7.3. North America CAR T Cell Therapy Market, 2015-2026
7.3.1. North America CAR T Cell Therapy Market Size and Forecast, 2015-2026
7.3.2. North America CAR T Cell Therapy Market by Country, 2015-2026
7.3.2.1. U.S. CAR T Cell Therapy Market, 2015-2026
7.3.2.2. Canada CAR T Cell Therapy Market, 2015-2026
7.4. Europe CAR T Cell Therapy Market, 2015-2026
7.4.1. Europe CAR T Cell Therapy Market Size and Forecast, 2015-2026
7.4.2. Europe CAR T Cell Therapy Market by Country, 2015-2026
7.4.2.1. Germany CAR T Cell Therapy Market, 2015-2026
7.4.2.2. France CAR T Cell Therapy Market, 2015-2026
7.4.2.3. Italy CAR T Cell Therapy Market, 2015-2026
7.4.2.4. UK CAR T Cell Therapy Market, 2015-2026
7.4.2.5. Spain CAR T Cell Therapy Market, 2015-2026
7.4.2.6. Rest of Europe CAR T Cell Therapy Market, 2015-2026
7.5. Asia Pacific CAR T Cell Therapy Market, 2015-2026
7.5.1. Asia Pacific CAR T Cell Therapy Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific CAR T Cell Therapy Market by Country, 2015-2026
7.5.2.1. Japan CAR T Cell Therapy Market, 2015-2026
7.5.2.2. China CAR T Cell Therapy Market, 2015-2026
7.5.2.3. India CAR T Cell Therapy Market, 2015-2026
7.5.2.4. Rest of Asia Pacific CAR T Cell Therapy Market, 2015-2026
7.6. South America CAR T Cell Therapy Market, 2015-2026
7.6.1. South America CAR T Cell Therapy Market Size and Forecast, 2015-2026
7.6.2. South America CAR T Cell Therapy Market by Country, 2015-2026
7.6.2.1. Mexico CAR T Cell Therapy Market, 2015-2026
7.6.2.2. Brazil CAR T Cell Therapy Market, 2015-2026
7.6.2.3. Rest of South America CAR T Cell Therapy Market, 2015-2026
7.7. Middle East & Africa CAR T Cell Therapy Market, 2015-2026
7.7.1. Middle East & Africa CAR T Cell Therapy Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa CAR T Cell Therapy Market by Country, 2015-2026
7.7.2.1. Saudi Arabia CAR T Cell Therapy Market, 2015-2026
7.7.2.2. South Africa CAR T Cell Therapy Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa CAR T Cell Therapy Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2018

9. Company Profiles
9.1. Novartis AG
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Kite Pharma
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. Pfizer, Inc.
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Cellectis
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Autolus Therapeutics PLC
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. CARsgen Therapeutics
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. Juno Therapeutics
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Sorrento Therapeutics
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Legend Biotech
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. Mustang Bio
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type